Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB123667 in Healthy Male Participants

NCT07218744 | Completed Phase 1 FDA Drug

• 1 other identifier: INCB123667-103
• Study Type: interventional
• Target: 9
• Locations: 1 country
• Sites: 1

Brief Summary

This study will assess the mass balance, pharmacokinetics, and metabolite profiles of a single oral dose of \[14C\] INCB123667 in healthy male participants.

Conditions

Healthy Participants

Keywords

INCB123667

Outcome Measures

Primary Outcomes (2)

• Total Recovery (Urine + Feces) of the Administered Radioactivity

  Radioactivity in urine and feces was reported as the percentage of the administered radioactivity excreted.

  Approximately 2 weeks

• Percentage of total radioactive dose in Plasma, Urinary and Fecal Excretion

  To characterize the metabolic profile and identify circulating and excreted metabolites of INCB123667 following administration of a single oral dose of INCB123667 followed by an oral dose solution of \[14C\]-INCB123667 using liquid chromatography with mass spectral detection.

  Up to approximately 2 months

Secondary Outcomes (13)

• PK for plasma INCB123667: Cmax

  Up to approximately 2 months

• PK for plasma INCB123667: tmax

  Up to approximately 2 months

• PK for plasma INCB123667: AUClast

  Up to approximately 2 months

• PK for plasma INCB123667: AUCinf

  Up to approximately 2 months

• PK for plasma INCB123667: t½

  Up to approximately 2 months

Study Arms (1)

Treatment: INCB123667

EXPERIMENTAL

Participants will be administered INCB123667 tablet orally, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB123667.

Drug: INCB123667

Interventions

INCB123667 DRUG

INCB123667 will be administered orally as a tablet dose, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB123667.

Treatment: INCB123667

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Ability to comprehend and willingness to sign a written ICF for the study.
• Healthy males age 18 to 55 years, inclusive, at the time of signing the ICF.
• Body mass index between 18.0 and 32.0 kg/m2, inclusive, at the time of screening.
• No clinically significant findings in screening evaluations (eg, clinical, laboratory, vital signs, ECG). Tests with results that fail eligibility requirements may be repeated once during screening if the investigator believes the results to be in error.
• Ability to swallow and retain oral medication.

You may not qualify if:

• History of clinically significant respiratory, renal, GI, endocrine, hematopoietic, psychiatric, and/or neurological disease.
• History of cardiovascular, cerebrovascular, peripheral vascular, or thrombotic disease or uncontrolled hypertension (systolic blood pressure \> 140 mmHg or diastolic blood pressure \> 90 mmHg at screening, confirmed by repeat testing).
• Presence of a malabsorption syndrome (eg, Crohn's disease or chronic pancreatitis) that could possibly affect drug absorption.
• Current or recent (≤ 6 months of screening), clinically significant gastrointestinal disease or surgery or any history of GI surgery (including cholecystectomy, excluding appendectomy and uncomplicated hernia repair) that is anticipated to affect the absorption of the study drug.
• Any major surgery within 6 months (≤ 6 months) of screening.
• Donation of blood to a blood bank or participation in a clinical study (except a screening visit) within 4 weeks of screening (within 2 weeks for donation of plasma only).
• Positive test for HBV, HCV, or HIV. Participants whose HBV results are compatible with prior immunization or immunity due to infection may be included at the discretion of the investigator.
• History of significant alcohol use within 3 months of screening, defined as regular alcohol consumption \> 21 units per week for males (1 unit = 0.5 pint of beer or a 25-mL shot of 40% spirit, 1.5 to 2 units = 125 mL glass of wine, depending on type).
• Positive urine or breath test result for ethanol or positive urine or serum screen for drugs of abuse that are not otherwise explained by permitted concomitant medications or diet.
• Current treatment or treatments within 30 days or 5 half-lives (whichever is longer) before the first dose of study drug on Day 1 with another investigational medication, or current enrollment in another investigational drug study.
• Participation in more than 3 radiolabeled drug studies in the last 12 months (previous study in which exposures are known to the investigator to be at least 4 months prior to check-in \[Day -1\]; previous studies in which exposures are not known to the investigator to be at least 6 months prior to check-in \[Day -1\]).
• Exposure to significant diagnostic or therapeutic radiation (eg, serial x-ray, computed tomography scan, barium meal) or employment in a job requiring radiation exposure monitoring within 12 months prior to check-in.
• Current treatment or treatment within 15 days or 5 half-lives (whichever is longer) before the first dose of study drug with any medications known to be an inducer or potent inhibitor of CYP3A4, BCRP, or P-gp (refer to the Certara Drug Interaction Database Program for prohibited medications).
• History of tobacco- or nicotine-containing product use within 1 month of screening. However, use of nicotine-containing products that is equivalent to ≤ 2 cigarettes per week may be permitted at the discretion of the investigator.

Sponsors & Collaborators

• Incyte Corporation: lead

Study Sites (1)

Fortrea Clinical Research Unit Ltd Labcorp Clinical Research Unit Limited Madison

Madison, Wisconsin, 53704, United States

Location

Related Links

• Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of \[14C\]-INCB123667 in Healthy Male Participants

Study Officials

• Incyte Medical Monitor

  Incyte Corporation

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 16, 2025
• First Posted: October 20, 2025
• Study Start: November 13, 2025
• Primary Completion: December 10, 2025
• Study Completion: December 10, 2025
• Last Updated: January 7, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)